RxDoctor Payments Data

Ryan Villarreal, MD

Internal Medicine · Winter Haven, FLNPI 1891359535

Payments from drug & device makers

$1,293in general payments, 2019–2025

Across 51 payments — averaging $25.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • Amgen$197
  • AstraZeneca$176
  • Boston Scientific$136
  • Exact Sciences$90
  • GSK$76
  • plus $393 from 13 others

What the payments were for

  • Food & beverage$1,27999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$121,507
Medicare patients
223
Services billed
5,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$55,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$44,736
ProliaDenosumab25$44,145
JardianceEmpagliflozin38$38,608
EntrestoSacubitril/Valsartan26$28,388
MounjaroTirzepatide21$24,840
OzempicSemaglutide22$22,958
FarxigaDapagliflozin Propanediol28$20,146
TrulicityDulaglutide19$19,658
XareltoRivaroxaban12$18,115
Tresiba Flextouch U-100Insulin Degludec17$14,668
BrilintaTicagrelor16$14,234
JanuviaSitagliptin Phosphate14$13,186
Spiriva RespimatTiotropium Bromide14$6,640
SymbicortBudesonide/Formoterol Fumarate14$6,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$55,40975 claims
GSKTrelegy Ellipta, Shingrix$76$47,71363 claims
Boehringer IngelheimJardiance, Spiriva Respimat$46$45,24852 claims
Lilly USA, LLCMounjaro, Trulicity$19$44,49840 claims
AmgenProlia$197$44,14525 claims
AstraZenecaFarxiga, Brilinta, Symbicort$176$40,70258 claims
Novo NordiskOzempic$225$22,95822 claims
MerckJanuvia$49$13,18614 claims
AbbVieSynthroid$19$3,44742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →